A recent report on castrate-resistant prostate cancer found that 7% of cases have missense or truncating mutations in BRCA2, and an additional 12% have alterations in other DNA repair/recombination genes associated with response to PARP inhibitors (15). The gene discussed is BRCA2; the disease is prostate carcinoma.